Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston.
JAMA Netw Open. 2020 Nov 2;3(11):e2027421. doi: 10.1001/jamanetworkopen.2020.27421.
The population impact of modifying obesity and other key risk factors for hyperuricemia has been estimated in cross-sectional studies; however, the proportion of incident gout cases (a clinical end point) that could be prevented by modifying such factors has not been evaluated.
To estimate the proportion of incident gout cases that could be avoided through simultaneous modification of obesity and other key risk factors.
DESIGN, SETTING, AND PARTICIPANTS: The Health Professionals Follow-up Study is a US prospective cohort study of 51 529 male health professionals enrolled in 1986 and followed up through questionnaires every 2 years through 2012. Self-reported gout cases were confirmed through June 2015. Clean and complete data used for this analysis were available in June 2016, with statistical analyses performed from July 2016 to July 2019.
From data collected in the validated questionnaires, men were categorized to low-risk groups according to combinations of the following 4 factors: normal body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; <25), no alcohol intake, adherence to Dietary Approaches to Stop Hypertension (DASH)-style diet (highest quintile of DASH diet score), and no diuretic use.
Population attributable risks (PARs) for incident gout meeting the preliminary American College of Rheumatology survey criteria, overall and stratified by BMI.
We analyzed 44 654 men (mean [SD] age, 54.0 [9.8] years) with no history of gout at baseline. During 26 years of follow-up, 1741 (3.9%) developed incident gout. Among all participants, PAR for the 4 risk factors combined (BMI, diet, alcohol use, and diuretic use) was 77% (95% CI, 56%-88%). Among men with normal weight (BMI <25.0) and overweight (BMI 25.0-29.9), we estimated that more than half of incident gout cases (69% [95% CI, 42%-83%] and 59% [95% CI, 30%-75%], respectively) may have been prevented by the combination of DASH-style diet, no alcohol intake, and no diuretic use. However, among men with obesity (BMI ≥30), PAR was substantially lower and not significant (5% [95% CI, 0%-47%]).
The findings of this cohort study suggest that addressing excess adiposity and other key modifiable factors has the potential to prevent the majority of incident gout cases among men. Men with obesity may not benefit from other modifications unless weight loss is addressed.
已有横断面研究估计了改变肥胖和其他高尿酸血症关键风险因素对人群的影响;然而,尚未评估通过改变这些因素可预防的痛风新发病例(临床终点)的比例。
评估同时改变肥胖和其他关键风险因素可避免的痛风新发病例比例。
设计、地点和参与者:健康专业人员随访研究是一项美国前瞻性队列研究,纳入了 1986 年登记的 51529 名男性健康专业人员,通过每 2 年一次的问卷进行随访,一直持续到 2012 年。通过 2015 年 6 月的痛风自我报告病例进行确认。2016 年 6 月可获得用于本分析的完整清洁数据,2016 年 7 月至 2019 年 7 月进行统计分析。
根据以下 4 个因素的组合,男性根据低风险组进行分类:正常体重指数(BMI[体重以千克为单位除以身高以米为单位的平方计算];<25)、不饮酒、遵循 DASH(停止高血压的饮食方法)饮食模式(DASH 饮食评分最高五分位)和不使用利尿剂。
符合美国风湿病学会初步调查标准的痛风新发病例的人群归因风险(PAR),总体和按 BMI 分层。
我们分析了 44654 名基线时无痛风病史的男性(平均[标准差]年龄,54.0[9.8]岁)。在 26 年的随访中,有 1741 名(3.9%)发生了痛风新发病例。在所有参与者中,BMI、饮食、饮酒和使用利尿剂 4 种风险因素联合的 PAR 为 77%(95%CI,56%-88%)。在体重正常(BMI<25.0)和超重(BMI 25.0-29.9)的男性中,我们估计超过一半的痛风新发病例(分别为 69%[95%CI,42%-83%]和 59%[95%CI,30%-75%])可能是通过 DASH 饮食、不饮酒和不使用利尿剂联合预防的。然而,在肥胖(BMI≥30)的男性中,PAR 显著较低且不显著(5%[95%CI,0%-47%])。
本队列研究的结果表明,解决超重和其他可改变的关键因素有潜力预防大多数男性痛风新发病例。肥胖男性可能不会受益于其他改变,除非解决体重问题。